

# 1 Adequacy of Nasal Self-Swabbing for SARS-CoV-2 Testing in Children

2  
3 Jesse J. Waggoner,<sup>1\*</sup> Miriam B. Vos<sup>1,2\*</sup>, Erika A. Tyburski,<sup>3\*</sup> Phuong-Vi Nguyen,<sup>1</sup> Jessica M. Ingersoll,<sup>1</sup>  
4 Candace Miller,<sup>1</sup> Julie Sullivan,<sup>1</sup> Mark Griffiths,<sup>2</sup> Cheryl Stone,<sup>2</sup> Macarthur Benoit,<sup>2</sup> Laura Benedict,<sup>2</sup>  
5 Brooke Seitter,<sup>2</sup> Robert Jerris,<sup>2</sup> Joshua M. Levy,<sup>1</sup> Colleen S. Kraft,<sup>1</sup> Sarah Farmer,<sup>3</sup> Amanda Foster,<sup>3</sup> Anna  
6 Wood,<sup>4</sup> Adrianna L. Westbrook,<sup>4</sup> Claudia R. Morris,<sup>1,2</sup> Usha N. Sathian,<sup>2</sup> William Heetderks,<sup>5</sup> Li Li,<sup>6</sup>  
7 Kristian Roth,<sup>6</sup> Mary Barcus,<sup>6</sup> Timothy Stenzel,<sup>7</sup> Greg S. Martin<sup>1+</sup>, and Wilbur A. Lam<sup>1,2,3+</sup>

8  
9 <sup>1</sup> Emory University School of Medicine, Atlanta, GA, USA

10 <sup>2</sup> Children's Healthcare of Atlanta, Atlanta, GA, USA

11 <sup>3</sup> Georgia Institute of Technology, Atlanta, GA, USA

12 <sup>4</sup> Pediatric Biostatistics Core, Department of Pediatrics, Emory University

13 <sup>5</sup> Consultant, National Institute of Biomedical Imaging and Bioengineering, NIH, Bethesda, MD

14 <sup>6</sup> Division of Microbiology, OHT7 Office of Product Evaluation and Quality, Center for Devices and  
15 Radiological Health, U.S. Food & Drug Administration

16 <sup>7</sup> OHT7 Office of Product Evaluation and Quality, Center for Devices and Radiological Health, U.S. Food  
17 & Drug Administration

18  
19 \* These authors contributed equally to this work

20 <sup>+</sup> Co-corresponding authors

21 **ABSTRACT**

22 **Background.** The goal of this study was to characterize the ability of school-aged children to self-collect  
23 adequate anterior nares (AN) swabs for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)  
24 testing.

25  
26 **Methods.** From July to August 2021, 287 children, age 4-14 years-old, were prospectively enrolled in the  
27 Atlanta area. Symptomatic (n=197) and asymptomatic (n=90) children watched a short instructional video  
28 before providing a self-collected AN specimen. Health care workers (HCWs) then collected a second  
29 specimen, and useability was assessed by the child and HCW. Swabs were tested side-by-side for SARS-  
30 CoV-2. RNase P RNA detection was investigated as a measure of specimen adequacy.

31  
32 **Results.** Among symptomatic children, 87/196 (44.4%) tested positive for SARS-CoV-2 by both self-  
33 and HCW-swab. Two children each were positive by self- or HCW-swab; one child had an invalid HCW-  
34 swab. Compared to HCW-swabs, self-collected swabs had 97.8% and 98.1% positive and negative  
35 percent agreements, respectively, and SARS-CoV-2 Ct values did not differ significantly between groups.  
36 Participants  $\leq 8$  years-old were less likely than those  $> 8$  to be rated as correctly completing self-collection,  
37 but SARS-CoV-2 detection did not differ. Based on RNase P RNA detection, 270/287 children (94.1%)  
38 provided adequate self-swabs versus 277/287 (96.5%) HCW-swabs ( $p=0.24$ ) with no difference when  
39 stratified by age.

40  
41 **Conclusions.** Children, aged 4-14 years-old, can provide adequate AN specimens for SARS-CoV-2  
42 detection when presented with age-appropriate instructional material, consisting of a video and a handout,  
43 at a single timepoint. These data support the use of self-collected AN swabs among school-age children  
44 for SARS-CoV-2 testing.

## 45 **Introduction**

46 As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has evolved, testing  
47 has become widely available for children and adults who may have coronavirus disease (COVID-19), the  
48 disease caused by SARS-CoV-2. However, testing capacity remains insufficient for repeat testing of  
49 asymptomatic school children and group settings for children, such as camps and schools, that are less  
50 likely to have trained health care workers (HCWs) available for sample collection. Long-standing medical  
51 practice has been to have a HCW collect samples for respiratory tract infection testing, which typically  
52 involves swabbing in the nose or mouth. Little data exists to suggest that HCW-collection is necessary,  
53 and it remains a barrier to expanding testing in locations with large numbers of children and limited  
54 access to healthcare personnel. Comparison of parental and nurse nasal swab collection for respiratory  
55 tract infection in children has demonstrated that nasal swab samples collected by parents are comparable  
56 to nurse-collected samples,<sup>1</sup> however even this has not become routine for younger children.

57  
58 Many SARS-CoV-2 tests have been authorized by the United States Food and Drug Administration  
59 (FDA) under Emergency Use Authorizations (EUAs) for self-swabbing by adults and children  $\geq 14$  years-  
60 old, and standardized instructions for self-swabbing of anterior nares (AN) are available. Many tests are  
61 also authorized by the FDA under EUA for parental swab sample collection for children  $\geq 2$  years-old. AN  
62 swabs are preferred for self-collection because they are technically less complex. However, the age at  
63 which nasal self-swabbing would generally be successful and how much it may affect sensitivity of  
64 COVID-19 testing is not known, and tests authorized by the FDA under EUA are not authorized for self-  
65 swabbing by children  $< 14$  years-old. Thus, there is a need to better understand at what age children can  
66 self-swab to provide a specimen for testing. This study was a collaboration between Emory University,  
67 Children's Healthcare of Atlanta, the Rapid Acceleration of Diagnostics (RADx) initiative of the National  
68 Institutes of Health National Institute of Biomedical Imaging and Bioengineering (NIH, NIBIB), and the  
69 FDA to generate data to support evidence-based recommendations to schools and other group settings  
70 with children regarding utilization of self-swabbing. Because the definition of an adequate sample was

71 undefined from our review of the literature, we conducted a multi-part study to answer the following  
72 study questions: 1) Are children, after hearing and seeing simple instructions, able to self-collect AN  
73 swabs for SARS-CoV-2 testing? 2) In children with suspected COVID-19, is self-swabbing as effective  
74 for detecting SARS-CoV-2 as HCW-swabbing? And 3) Can RNase P RNA serve as an indicator of AN  
75 swab specimen adequacy during periods of low respiratory virus transmission?

76

## 77 **Methods**

78 **Ethics statement.** All studies were approved by the Emory University IRB and all participants provided  
79 consent (and assent, where indicated by age) prior to participating.

80

81 **Symptomatic children.** A prospective cohort of symptomatic SARS-CoV-2 positive and negative  
82 children was recruited into a cross sectional study to compare self-swabbing to HCW-swabbing for  
83 SARS-CoV-2 detection. Symptomatic children were recruited based on a daily report generated of all  
84 children testing positive by standard of care nasopharyngeal (NP) swab within the Children's Healthcare  
85 of Atlanta System in the previous 24 hours. Target enrollment was 10 COVID-positive and 10 COVID-  
86 negative children in each age group. Parents were called and asked to return to a Drive-Thru testing site  
87 set up at the Center for Advanced Pediatrics. Children were excluded if self-swabbing was not feasible  
88 due to a medical condition; developmental delay precluded the child from understanding the instructions  
89 in the opinion of the parent (or guardian); or the child had a history of nosebleeds in the past 2 weeks. If a  
90 SARS-CoV-2-positive child returned for the self-swabbing study  $\geq 48$  hours after their most recent  
91 positive test, a repeat, standard-of-care NP COVID test was obtained after AN swab collection for the  
92 current study.

93

94 Once consented, a video of children teaching and demonstrating how to self-swab was shown, and  
95 children were provided with an instructional handout with images on one side and images plus written  
96 instructions on the other (Supplemental Material). The child then performed the self-swab followed by the

97 HCW. The instructions in the video and handout were used as the process for swabbing. Four rotations of  
98 a Nylon Flocked Swab (regular size with 30mm breakpoint; Copan Diagnostics, Murrieta, CA) were  
99 performed in each naris. Then the swab was given to the HCW, who placed it in a sterile cryovial pre-  
100 filled with 1mL saline. The same process was repeated by the HCW. The 3 HCWs who conducted all  
101 swabbing for this project were highly skilled and experienced pediatric nurses. Following collection,  
102 samples were immediately placed on ice and transported to the laboratory by courier at the end of each  
103 day. Samples were stored at 4°C for up to 72 hours prior to nucleic acid extraction and testing. If the  
104 expected duration of storage exceeded 72 hours, samples were stored at -80°C.

105

106 **RNase P RNA detection – Pilot study.** The overall study was planned and initiated during the nadir in  
107 SARS-CoV-2 transmission that occurred during the spring and early summer of 2021.<sup>2</sup> As such, RNase P  
108 RNA detection was evaluated as an investigational measure of specimen adequacy. A retrospective pilot  
109 study was conducted to determine if RNase P RNA could be detected in HCW-collected AN samples.  
110 A set of 24 archived AN samples from asymptomatic children age 5 to 17 years were sourced from the  
111 Children’s Clinical and Translational Discovery Core, then re-extracted and tested using the  
112 investigational study protocol for RNase P RNA detection. Selected samples included 12 without  
113 detectable SARS-CoV-2 RNA and 12 with detectable SARS-CoV-2 RNA grouped by cycle threshold  
114 (Ct): 4 samples each having Cts of <24, 24-32, and >32. All had been stored at -80°C in normal saline  
115 until extraction.

116

117 **Asymptomatic children.** Following completion of the pilot study evaluating RNase P RNA detection,  
118 asymptomatic children were prospectively enrolled, with a target enrollment of 10 children per year of  
119 age from 5 to 12 years. Recruitment was conducted through a metro Atlanta neighborhood social media  
120 page. Parents were invited to sign their child/children up for 15-minute time slots over the course of 2  
121 days. An outdoor testing tent was set up near the neighborhood clubhouse. Children came with their  
122 parents and consent and assent were obtained. A small number of children were recruited by word of

123 mouth to target specific ages that were needed to achieve the target enrollment following these 2 days. In  
124 addition to the exclusion criteria for symptomatic children, asymptomatic children were also excluded if  
125 COVID-19 had been suspected/diagnosed in the past 30 days or if the child had current respiratory  
126 symptoms or other COVID-19 symptoms in the past 2 weeks. Children observed the same video and were  
127 provided with the same instructional handout prior to self-swabbing, as described above. The research  
128 team of nurses and research coordinators followed the same process as described for the symptomatic  
129 cohort.

130

131 **Usability evaluation.** A set of usability questions was developed with the goal of determining the  
132 feasibility and overall experience of self-swabbing by children (Supplemental Material). The aim of the  
133 questions was to determine if all tasks associated with self-swabbing were completed correctly, whether  
134 participants required any assistance, how participants felt about self-swabbing, and whether participants  
135 understood the instructions. A portion of the questions were HCW-facing; that is, the HCW conducting  
136 the study observed participant actions and responded to questions accordingly. The remaining questions  
137 were participant-facing. The usability questionnaire was completed immediately after sample collection  
138 by the child and HCW. The child received assistance from the HCW, as needed, to complete the usability  
139 questionnaire.

140

141 Given that the HCWs administering the questions were also focused on conducting the study, the data  
142 entry required was intended to be minimally disruptive. The participant-facing questions came with a  
143 separate set of considerations, as the participants were children. The vocabulary used in the questions was  
144 selected to be accessible to the age groups included in the study. Questions were designed to be non-  
145 leading and open-ended where possible, and used prompts such as “can you tell me about....,” as these  
146 methods have been shown to elicit more complete and accurate information from children.<sup>3,4</sup> Questions  
147 were designed to be answered with a *yes/no* selection, selection from a list of options, or, for participant-  
148 facing questions, one to two words summing up responses to open-ended questions.

149

150 **SARS-CoV-2 molecular testing.** All samples from symptomatic participants and the single  
151 asymptomatic participant with SARS-CoV-2 were extracted and tested with the CDC 2019-Novel  
152 Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel (hereinafter referred to as the CDC EUA  
153 rRT-PCR) according to the instructions for use.<sup>5</sup> Briefly, 100 $\mu$ L of sample was extracted on a Roche  
154 MagNA Pure 96 using the DNA and Viral NA Small Volume Kit (Roche, Basel, Switzerland). Nucleic  
155 acids were eluted in 100 $\mu$ L and immediately tested for the N1, N2 and RNase P in separate 20 $\mu$ L  
156 reactions of the TaqPath 1-Step RT-qPCR Master Mix (Thermo Fisher, Waltham, MA) on an ABI Fast  
157 DX Real-Time PCR system (Thermo Fisher). Results were interpreted according to the instructions for  
158 use.<sup>5</sup> All samples with inconclusive results were re-tested by rRT-PCR, and samples with invalid results  
159 were re-extracted and re-tested.

160

161 **Investigational RNase P RNA detection.** All samples were tested for SARS-CoV-2 and RNase P RNA  
162 with an investigational study protocol. Total nucleic acids were extracted from 200 $\mu$ L of AN sample and  
163 eluted into 50 $\mu$ L on an EMAG instrument (bioMérieux, Durham, NC). Following extraction, 12 $\mu$ L of  
164 eluate was DNase treated in 25 $\mu$ L reactions of the Heat&Run gDNA Removal Kit (ArticZymes, Tromsø,  
165 Norway) according to manufacturer recommendations. Resulting RNA was immediately tested by real-  
166 time RT-PCR (rRT-PCR) for the nucleocapsid 2 (N2) target and RNase P. The assay was run as duplex  
167 test but otherwise performed as described.<sup>6</sup> A specimen was considered to have detectable SARS-CoV-2  
168 or RNase P RNA if it yielded a Ct value  $\leq$  40 for that target in the duplex assay. Samples from 21  
169 children with detectable SARS-CoV-2 RNA were also tested in a multiplex rRT-PCR for specific *spike*  
170 mutations associated with variants of concern. This assay was performed, as described,<sup>7,8</sup> using DNase-  
171 treated RNA.

172

173 **Statistical analysis.** For analysis of test outcomes, concordant pairs were defined as specimen pairs that  
174 generated the same qualitative result with the CDC EUA rRT-PCR. Negative concordant pairs had

175 undetectable SARS-CoV-2 RNA but detectable signal for RNase P. Positive concordant pairs had  
176 detectable SARS-CoV-2 RNA. Useability data were evaluated by age and when binned as  $\leq 8$  and  $> 8$   
177 years-old, based on initial review of the results. Descriptive statistics for the study were reported as  
178 medians and interquartile ranges for continuous variables and counts with percentages for categorical  
179 variables. Shapiro-Wilk tests were used to check normality of continuous data. Two-group comparisons  
180 were conducted using students t-tests for normally distributed continuous data. Wilcoxon rank-sum tests  
181 were used for non-normal continuous data. Categorical data was compared using chi-squared tests  
182 or Fisher's exact tests for expected cell counts  $< 5$ . Statistical significance was assessed at the 0.05 level.  
183 All statistical analyses were conducted using SAS 9.4 (Cary, NC).

184

## 185 **Results**

186 **Symptomatic children.** 197 symptomatic children, aged 4-14 years-old, were enrolled in July-August  
187 2021 (Figure 1). A single HCW-collected swab was invalid (no detectable SARS-CoV-2 or RNase P  
188 RNA), and this participant was removed from further analysis (self-swab, negative). 87 children (44.4%)  
189 tested positive for SARS-CoV-2 by both self- and HCW-swabs (positive concordant samples), and two  
190 children each tested positive by self- or HCW-swab, but negative by the alternate swab. Positive and  
191 negative percent agreements were 97.8% and 98.1%, respectively ( $\kappa = 0.96$ , 95% CI: 0.92 to 0.99;  
192 Figure 2A). Children with concordant positive SARS-CoV-2 rRT-PCR results presented, on average, one  
193 day later than children who tested negative [days post-symptom onset, median 3 (IQR 1-4) vs 2 (1-3),  
194 respectively;  $p=0.002$ ]. These two groups were otherwise similar (Table 1). N2 Ct values obtained with  
195 the CDC EUA rRT-PCR did not differ between self- and HCW-collected swabs among the 87 children  
196 with SARS-CoV-2 detected in both samples (Figure 2B).

197

198 For 28 participants (32.9%), N2 Ct values differed by  $> 3.3$  cycles between self- and HCW-collected  
199 swabs, consistent with  $\sim 10$ -fold difference in viral RNA concentration. 12 children (14.1%) had lower Ct  
200 values (greater RNA) in self-collected swabs and 16 (18.8%) had lower Ct values in HCW-collected



201 swabs (Figure 3C). Children with lower Ct values in the self-collected swab were more likely to be  
202 black/African American and present earlier in the course of illness. No other differences were noted  
203 between these groups (Table S1). Finally, 4 participants had discordant qualitative SARS-CoV-2 results;  
204 all had N2 Ct values > 30.0 from the positive sample (Figure 2D, Table 2).

205  
206 **Investigational RNase P RNA detection.** In the retrospective pilot study, RNase P was detected in AN  
207 swabs from all 24 asymptomatic children. RNase P Cts were significantly higher in DNase treated versus  
208 untreated eluates (mean Ct  $31.6 \pm 2.7$  vs.  $23.8 \pm 2.6$ , respectively;  $p < 0.001$ , Figure S1A). RNase P RNA  
209 Cts did not differ significantly between samples with and without detectable SARS-CoV-2 RNA or based  
210 on the SARS-CoV-2 Ct in positive samples (Figure S1B and C). Based on the pilot data, 90 asymptomatic  
211 children, aged 5-12 years-old, were enrolled in July 2021 (Figure 1), and all self- and HCW-collected  
212 swabs from symptomatic and asymptomatic children were tested with the investigational study protocol.

213  
214 For this phase of the study, an adequate specimen was defined as a specimen with detectable RNase P or  
215 SARS-CoV-2 RNA by rRT-PCR. Overall, 270/287 children (94.1%) provided adequate self-swabs versus  
216 277/287 (96.5%) HCW-swabs based on RNase P RNA detection ( $p=0.24$ ). Among symptomatic children,  
217 there was no difference in specimen adequacy overall or stratified by age. However, one or both swabs  
218 from 19 participants would have been considered inadequate based on RNase P RNA detection alone: 9  
219 self-swabs, 9 HCW-swabs, and 1 both swabs (Figure S2). For asymptomatic children, all HCW-collected  
220 and 83 self-collected swabs were considered adequate ( $p=0.01$ ; Table 3, Figure S3A). RNase P RNA Ct  
221 values were similar for children who had adequate self- and HCW-swabs (Figures S2C and S3B). A  
222 single individual had detectable SARS-CoV-2 RNA, which was detected in both the self- and HCW-  
223 collected swab. This result was confirmed in the CDC EUA rRT-PCR. Notably, 4 individuals with  
224 inadequate self-swabs on the first attempt were re-contacted and were trained again on self-swabbing. All  
225 self-swabs from the repeat collection had detectable RNase P RNA.

226

227 Finally, 21 samples were tested for Spike receptor binding domain mutations; 18/21 (85.7%) had  
228 interpretable results and had evidence of infection with delta variant (K417, L452R, T478K).

229  
230 **Usability analysis.** Children  $\leq 8$  years-old were more likely than those  $> 8$  years-old to be scored as  
231 having difficulty performing AN swab collection [37/134 (27.6%) vs. 19/147 (12.9%), respectively;  
232  $p=0.003$ ] and requiring assistance [29/133 (21.8%) vs. 9/147 (6.1%);  $p<0.001$ ], and they were less likely  
233 to be rated as having completed sample collection correctly [82/133 (61.6%) vs. 122/146 (83.6%);  
234  $p<0.001$ ; Table S2 and S3]. The most common type of assistance provided was instructional regarding  
235 how to swab the nostrils. Despite these findings, the proportion of adequate samples, defined as either  
236 SARS-CoV-2 RNA detection in the CDC EUA rRT-PCR or RNase P RNA detection, was similar for  
237 asymptomatic and symptomatic children  $\leq 8$  and  $> 8$  years old.

## 238 239 **Discussion**

240 The COVID-19 pandemic has illuminated the need for increased testing capacity across all age groups.  
241 Although SARS-CoV-2 testing capacity has dramatically increased, namely due to new testing  
242 technologies receiving EUA and deployed for lab and non-lab settings, many testing schemas involve  
243 HCWs for sampling. There have been several tests and collection kits deployed for use in the home which  
244 utilize self-collection and collection from children by their parents or guardians, but few options exist for  
245 pediatric self-collection. This has made it challenging to test and screen pediatric populations due to the  
246 need for trained individuals at the school or group setting to collect samples. One prior study investigated  
247 the feasibility of AN swab self-collection by school-aged children based on the rate of observed  
248 deviations from a standard collection protocol, but results of molecular testing were not reported.<sup>9</sup> In  
249 contrast, the studies presented here characterized the ability of school-aged children to adequately self-  
250 collect AN samples based on the results of SARS-CoV-2 molecular testing and evaluated the useability of  
251 self-collection from both the child and HCW perspective.

252  
253 When provided with video and printed instructions, children in all tested age groups were able to  
254 adequately self-collect AN samples for the purposes of SARS-CoV-2 testing. There was no significant  
255 bias or improvement in performance based on collected demographic variables. These findings support  
256 that pediatric self-collection can be used for SARS-CoV-2 testing and could decrease the burden of HCW  
257 requirements in existing testing strategies. Additionally, the results support the potential for non-  
258 traditional testing schemas for children, including self-collection and sample drop off at schools, prior to  
259 events, and even testing at home. These results fill an important void and contribute to the scarce data that  
260 exists on pediatric involvement in ongoing testing efforts.

261  
262 This study was planned and initiated during a nadir in COVID-19 cases in Georgia. Detection of SARS-  
263 CoV-2 RNA was the preferred endpoint, but with low rates of infection during the planning phase of the  
264 study, additional exploratory outcome measures were considered. As such, RNase P RNA was evaluated  
265 as an ancillary measure of specimen adequacy. This required an additional step following nucleic acid  
266 extraction to remove genomic DNA, which is also detected in the RNase P assay that is commonly used  
267 as a specimen control.<sup>5</sup> RNase P RNA was detectable in the majority of AN swabs, with no significant  
268 difference between self- and HCW-collected samples. One or both swabs from 19 symptomatic and 7  
269 self-swabs from asymptomatic participants were considered inadequate based on RNase P RNA  
270 detection. However, no meaningful difference in SARS-CoV-2 RNA detection using the CDC EUA rRT-  
271 PCR was detected, which was the primary outcome measure of the study. These data indicate that,  
272 although RNase P RNA detection provides a rigorous indicator of specimen adequacy, it may be a more  
273 demanding measure than viral RNA detection and overestimate collection failure.

274  
275 There are a few limitations to the work presented. Data comparing SARS-CoV-2 detection in self- versus  
276 HCW-collected samples were limited to symptomatic participants, and there was not sufficient statistical  
277 power to detect small differences in SARS-CoV-2 detection by year of age. There was only one

278 asymptomatic child who tested positive for SARS-CoV-2, which did result in positive results for both  
279 self- and HCW-collected samples. Further testing should be done to confirm that self-collection is  
280 effective for SARS-CoV-2 testing in an asymptomatic pediatric population.

281

282 Given the similar performance of self- and HCW-collected AN swabs, data from the current study support  
283 the development of SARS-CoV-2 testing plans for school aged children that allow for self-collection.

284 Such strategies have the potential to improve testing capacity by decreasing the need for trained staff at  
285 collection sites, and future work could evaluate the use of self-collected samples for multiplex respiratory  
286 viral testing to reduce outbreaks in this population.

287 **Acknowledgements**

288 The authors thank the participants and their families for participation in this study. We acknowledge the  
289 contributions of Children’s Healthcare of Atlanta Research Coordinators Misty McGhee, Lauren  
290 Robinsons, and Rashad Wood on this project. We also acknowledge the helpful comments and feedback  
291 from Emory RADx team members during all phases of the study. The Children’s Clinical and  
292 Translational Discovery Core is generously supported by Children's Healthcare of Atlanta and Emory  
293 University.

294

295 **Conflicts of Interest**

296 None.

297

298 **Funding Sources**


299 This work was supported by the National Institute of Biomedical Imaging and Bioengineering at the  
300 National Institutes of Health under award Numbers U54 EB027690-03S1 and U54 EB027690-03S2 and  
301 the National Center for Advancing Translational Sciences of the National Institutes of Health under  
302 Award Number UL1TR002378. The content is solely the responsibility of the authors and does not  
303 necessarily represent the official views of the National Institutes of Health.

304 **References**


- 305 1. Woodall CA, Thornton HV, Anderson EC, et al. Prospective Study of the Performance of Parent-  
306 Collected Nasal and Saliva Swab Samples, Compared with Nurse-Collected Swab Samples, for the  
307 Molecular Detection of Respiratory Microorganisms. *Microbiol Spectr* 2021;9:e0016421.
- 308 2. Daily Status Report. 2021. (Accessed 19 Nov 2021, 2021, at [https://dph.georgia.gov/covid-19-](https://dph.georgia.gov/covid-19-daily-status-report)  
309 [daily-status-report.](https://dph.georgia.gov/covid-19-daily-status-report))
- 310 3. Waterman AH, Blades M, Spencer C. Interviewing children and adults: The effect of question  
311 format on the tendency to speculate. *Applied Cognitive Psychology* 2001;15:521-31.
- 312 4. Cameron H. Asking the tough questions: a guide to ethical practices in interviewing young  
313 children. *Early Child Development and Care* 2005;175:597-610.
- 314 5. Centers for Disease Control and Prevention. Real-Time RT-PCR Panel for Detection 2019-Novel  
315 Coronavirus, Instructions for Use. 2020.
- 316 6. Waggoner JJ, Stittleburg V, Pond R, et al. Triplex Real-Time RT-PCR for Severe Acute  
317 Respiratory Syndrome Coronavirus 2. *Emerging infectious diseases* 2020;26:1633-5.
- 318 7. Babiker A, Immergluck K, Stampfer SD, et al. Single-amplicon, multiplex real-time RT-PCR  
319 with tiled probes to detect SARS-CoV-2 spike mutations associated with variants of concern. *Journal of*  
320 *clinical microbiology* 2021;JCM0144621.
- 321 8. Martinez M, Nguyen P-V, Su M, et al. SARS-CoV-2 variants in Paraguay: Detection and  
322 surveillance with a readily modifiable, multiplex real-time RT-PCR. *medRxiv*  
323 2021:2021.09.15.21263618.
- 324 9. Altamirano J, Lopez M, Robinson IG, et al. Feasibility of Specimen Self-collection in Young  
325 Children Undergoing SARS-CoV-2 Surveillance for In-Person Learning. *JAMA Netw Open*  
326 2022;5:e2148988.

327

328 **Figures**



329  
330 **Figure 1. Study flowchart for samples from prospectively enrolled asymptomatic and symptomatic**  
331 **children.** Self- and HCW-collected samples that yielded the same qualitative rRT-PCR result were  
332 considered concordant. \* One child tested self-swab negative and HCW-swab invalid (no detectable  
333 RNase P).



335 **Figure 2. SARS-CoV-2 RNA detection does not differ between self- and HCW-collected nasal swabs**  
336 **in symptomatic children.** A) 2x2 comparison of qualitative SARS-CoV-2 detection, B) overall  
337 distribution of SARS-CoV-2 N2 target Ct values, and C) paired SARS-CoV-2 N2 Ct values for self- and  
338 HCW-collected swabs. D) Ct values for the positive sample from 4 discrepant sample pairs where SARS-  
339 CoV-2 RNA was only detectable in the self-collected (n=2) or HCW-collected (n=2) specimen. All  
340 displayed results were obtained with the CDC EUA rRT-PCR.



341 **Table 1.** Characteristics of symptomatic children with concordant SARS-CoV-2 positive vs. SARS-CoV-  
 342 2 negative samples.

Category, n (%)	Participants with concordant results			P-Value <sup>b</sup>
	All Participants <sup>a</sup>	SARS-CoV-2	SARS-CoV-2	
		Detected	Not Detected	
	N=196	N=87	N=105	
Gender				0.244
Female	86 (44.3%)	42 (49.4%)	43 (41.0%)	
Male	108 (55.7%)	43 (50.6%)	62 (59.1%)	
Ethnicity				0.812
White	53 (28.3%)	26 (31.3%)	27 (27.0%)	
Black/African American	120 (64.2%)	51 (61.5%)	66 (66.0%)	
Hispanic	9 (4.8%)	3 (3.6%)	5 (5.0%)	
Other	5 (2.7%)	3 (3.6%)	2 (2.0%)	
Age in years, median (IQR)	9 (6, 11)	9 (7, 11)	8 (6, 11)	0.132
Age Group				0.562
≤5	26 (13.3%)	8 (9.2%)	17 (16.2%)	
6	24 (12.2%)	9 (10.3%)	15 (14.3%)	
7	24 (12.2%)	10 (11.5%)	14 (13.3%)	
8	19 (9.7%)	9 (10.3%)	10 (9.5%)	
9	21 (10.7%)	13 (14.9%)	8 (7.6%)	
10	16 (8.2%)	9 (10.3%)	6 (5.7%)	
11	23 (11.7%)	9 (10.3%)	14 (13.3%)	
12	18 (9.2%)	8 (9.2%)	9 (8.6%)	
13-14	25 (12.8%)	12 (13.8%)	12 (11.4%)	
Days post-symptom onset, median (IQR)	2 (1, 4)	3 (1, 4)	2 (1, 3)	<b>0.002</b>
Q4. Did the participant require assistance?				0.598
No	162 (85.7%)	73 (86.9%)	85 (84.2%)	
Yes	27 (14.3%)	11 (13.1%)	16 (15.8%)	
Q5. Was the swab collection completed correctly?				0.172
No	47 (25.0%)	25 (29.8%)	21 (21.0%)	
Yes	141 (75.0%)	59 (70.2%)	79 (79.0%)	

343 <sup>a</sup> 2 participants missing gender, 9 missing race/ethnicity, 7 missing Q4, 8 missing Q5

344 <sup>b</sup> P-value is for the comparison of the concordant results groups

345

346 **Table 2.** Characteristics of participants with discordant SARS-CoV-2 results between self- and HCW-  
347 collected AN swabs tested in the CDC EUA rRT-PCR.

Positive swab	SARS-CoV-2 N2 Ct	Age	Gender	Race	Ethnicity	Did the participant require assistance?	Was the self-swab collection completed correctly?
<i>Self-collected swab</i>							
Patient 8232	31.02	12	Male	Black/African American	Non-Hispanic	No	Yes
Patient 8298	38.10	14	Male	Black/African American	Non-Hispanic	No	Yes
<i>HCW-collected swab</i>							
Patient 8113	30.38	10	Male	Black/African American	Non-Hispanic	No	Yes
Patient 8244	33.87	4	Female	Patient's race missing	Hispanic	No	No

348

349 **Table 3.** Characteristics of asymptomatic children categorized based on concordant and discordant results  
 350 for investigational RNase P RNA detection between self- and HCW-collected AN swabs.

Category, n (%)	Self-Collection Results			P-Value
	All Participants	Concordant	Discordant	
	N=90	N=83	N=7	
Age				0.672
≤5	11 (12.2%)	10 (12.0%)	1 (14.3%)	
6	9 (10.0%)	8 (9.6%)	1 (14.3%)	
7	13 (14.4%)	12 (14.5%)	1 (14.3%)	
8	10 (11.1%)	10 (12.0%)	0 (0.00%)	
9	14 (15.6%)	12 (14.5%)	2 (28.6%)	
10	13 (14.4%)	12 (14.5%)	1 (14.3%)	
11	15 (16.7%)	15 (18.1%)	0 (0.00%)	
12	5 (5.6%)	4 (4.8%)	1 (14.3%)	
Q4. Did the participant require assistance?				1.000
No	79 (87.8%)	73 (88.0%)	6 (85.7%)	
Yes	11 (12.2%)	10 (12.0%)	1 (14.3%)	
Q5. Was the swab collection completed correctly?				0.673
No	28 (31.1%)	25 (30.1%)	3 (42.9%)	
Yes	62 (68.9%)	58 (69.9%)	4 (57.1%)	